Announcements

U.S. News Best Hospitals Voting
With your help, we can continue to push our reputation score higher in U.S. News & World Report's annual Best Hospital's Guide. I hope we can work together to improve our reputation score, and our ranking.

Please support our institution by participating in this year's survey. Online voting for reputation scores is open through Doximity or on the Doximity app. I encourage each of you to take a few minutes to vote and support cancer services at Smilow Cancer Hospital. When making your selection, you can type Smilow or Yale and Smilow Cancer Hospital at Yale New Haven (New Haven, CT) will appear for you to select.
New Leadership on NP12

Please join me in welcoming Elizabeth Prsic, MD, Assistant Professor of Internal Medicine and Director of Adult Inpatient Palliative Care, and Paul Eder, MD, Professor of Medicine (Medical Oncology) to their roles as Firm Chiefs on North Pavilion 12. Dr. Prsic has been appointed North Pavilion 12 Firm Chief - Operations and Quality and Dr. Paul Eder North Pavilion 12 Firm Chief - Education and Oncology Practice.

In her role, Dr. Prsic brings expertise in palliative care, medical oncology, and hospital operations. She will serve as the central physician partner, alongside our nursing leadership, in our ongoing clinical redesign efforts as we aim to continuously improve the inpatient care experience for our patients and their families. Dr. Eder has long been recognized as a master educator and clinician and brings decades of clinical oncology experience to NP12. He will ensure that the educational experience for fellows, residents, and trainees is absolutely first rate, while always prioritizing our patients' needs first. I would like to thank Dr. Tara Sanft for her outstanding leadership on NP12 over the past several years, and look forward to working with her more closely in her new role as Chief Experience Officer.

Meet our Remarkable Woman Finalist: Sandra Morgan
Read More >>

Yale Cancer Center Scientists Find New Way to Block Cancer-Causing HPV Virus
Read More >>

Battling a Brain Tumor, a Super Bowl Surprise for a Smilow Cancer Patient
Read More >>

Join Smilow Cancer Hospital on Facebook
Appointments
I am pleased to announce several leadership appointments for the Smilow Cancer Hospital Care Centers. Effective March 16, Jeremy Kortmansky, MD, will be appointed Deputy Chief Network Officer for the Care Center Network. Dr. Kortmansky practices in our North Haven Care Center and specializes in the treatment of patients with gastrointestinal cancers. His leadership and continued engagement in clinical priorities over the past several years as Program Leader for GI Cancers and Medical Director of the North Haven Care Center will transition seamlessly into his new position. In his new role, he will partner closely with Dr. Anne Chiang, Chief Network Officer, to share oversight of the network medical oncology and hematology practice, including standards of care, clinical integration, physician recruitment, and faculty development, education, and advisement.

"It's an exciting time at Yale, with a contagious enthusiasm among basic scientists and clinical investigators to collaborate on efforts to understand sensitivity and resistance to current immunotherapies, and develop the next generation of immunotherapies," Dr. Scott Gettinger. Read how Smilow Cancer Hospital and Yale Cancer Center are celebrating 10 Years of Leadership in Immunotherapy.

March is Kidney Cancer Awareness Month. Take a few minutes to read Tammy's story of courage. Her instincts and eventual trust in her surgical team at Smilow Cancer Hospital helped lead her to cure after a difficult kidney cancer diagnosis.
Jane Kanowitz, MD, will be appointed Medical Director for the Smilow Cancer Hospital Care Center in North Haven, transitioning her practice from Waterford effective March 16. Jane’s practice leadership and ability to build a multidisciplinary breast cancer practice in Southeastern Connecticut will serve our newly expanded Care Center in North Haven well. In her new position, she will partner with Dr. Kortmansky, Dr. Armand Russo, and the entire oncology team in North Haven, as well as with Dr. Terri Parker, Assistant Medical Director of the care center in North Haven for the Hematology Program.

Effectively immediately, M. Sung Lee, MD, has been appointed Interim Medical Director of the Smilow Cancer Hospital Care Center in Greenwich. In his new position, Dr. Lee will work closely with Dr. Dickerman Hollister, Jr.,

March is Colorectal Cancer Awareness Month. Learn more about the physicians and caregivers here to help patients needing care through the Gastrointestinal Cancers Program at Smilow Cancer Hospital.

On Yale Cancer Answers, Smilow Cancer Hospital social workers Laura Donnelly and Jessica Stein discuss the important role of social work on our cancer care teams. Tune in to hear their perspective, and how you can access social work assistance during your care.

Yale Cancer Center is pleased to welcome Raul Hernandez-Ramirez, PhD and Wei Wei, MD, PhD, to the Cancer Prevention and Control Research Program. Dr. Hernandez-Ramirez’s cancer research contributions are focused on the etiology of cancer in people living with HIV, breast cancer, and gastric cancer. More recently, he has been conducting
who has led the medical oncology care in Greenwich for nearly 40 years and will continue to practice and care for women with breast cancer at our Care Center. Dr. Lee has practiced medical oncology and hematology in Greenwich since 2001. His clinical interests include caring for patients with hematologic and thoracic malignancies.

**T-TAREs Awarded**
The Office of Translational Research is pleased to announce recipients of this year’s first round of Translational-Targeted Area of Research Excellence (T-TARE) funding:

- **Yale Brain SPORE Team**, led by Murat Gunel, MD, and Antonio Omuro, MD ($150,000)

- **Optimization of Cellular Immunotherapy for Melanoma**, led by Marcus Bosenberg, MD, PhD, and Samuel Katz, MD, PhD ($100,000)

- **Mechanisms and Biomarkers for Combinatorial Treatment of Solid Tumors with BETi and HDACi**, led by Qin Yan, PhD, and Patricia LoRusso, DO ($150,000)

Dr. Wei’s current research focuses on the development of early phase clinical trial designs, with particular interest in continuous monitoring of toxicity-eficacy outcomes and model-based definitions of clinical benefit. Dr. Wei developed a statistical method to redefine trial eligibility for adjuvant trials based on residual risk.

Dr. Jennifer Moliterno, noticed a small detail about her patient Maurice W., that was about to make a big difference. She reached out to research related to cancer in people living with HIV and is beginning new research on prevention of cervical cancer and other HPV-related cancers with a focus on Mexico and U.S. Hispanic populations.
The T-TARE program, led by Edward Kaftan, PhD, Associate Director for Translational Research Administration, provides support of up to $200,000 for teams of three or more investigators led by a Yale Cancer Center member. Awards support research with a significant translational or clinical component, such as investigator-initiated trials, toward the goal of developing multidisciplinary NCI grant submissions, including P01 or SPORE grants. The T-TARE program will award $1.5M over the next two years; Upcoming quarterly submission deadlines are April 30, July 31, October 30, and January 31. For more information, please contact Edward Kaftan, PhD.

Notables

George Goshua, MD, Hematology-Oncology Fellow, was invited to give Genetics Clinical Grand Rounds earlier this week. His talk, Rare Disease Impact: A Journey to the Heart of Medicine, honed in on equity in diagnosis and treatment for the 300 million people worldwide living with rare disease and supported the efforts of the European Organization for Rare Diseases and the National Organization for Rare Disorders. Additionally, Dr. Goshua was selected to lead the Hemostasis and Thrombosis Research Society Fellows Network, the North American professional medical society advancing care for people with hemostatic and thrombotic disorders. He will serve as Chair Elect beginning April 2021.

Prasanna Ananth, MD, has been selected to receive an American Academy of Hospice and Palliative Medicine Paper Award for her proposal, "What Defines High Quality End-of-Life Care for Children with Cancer? A Stakeholder-Driven Qualitative Study." Dr. Ananth will present the paper at their conference on March 20.

Dr. Lieping Chen gave the 2020 Enrico Mihich Lecture on January 31 at Roswell Park Cancer Center to her friends at The Lovemark Foundation to help. To Maurice, what seemed to be a check-up visit, turned out to be any The Kansas City Chiefs fan's dream!

Katerina Politi and En Cheng joined colleagues from Cancer Centers across the country in Washington today to participate in #AACRontheHill to talk to lawmakers about the importance of funding cancer research. Thank you for representing Yale Cancer Center and Smilow Cancer Hospital!
Institute in Buffalo, NY. The Dr. Enrico Mihich Lecture was created in 2007 to honor a lifetime achievement in cancer research by Dr. Mihich, Distinguished Member of the Department of Pharmacology and Therapeutics at Roswell Park. During the 2020 Enrico Mihich Lecture, Dr. Chen discussed, “What have we learned from anti-PD therapy and what is next?”

The Genomics, Genetics, and Epigenetics Research Program welcomes Christine Ko, MD, Professor of Dermatology and Pathology. Dr. Ko has expertise in both dermatology and dermatopathology, with access to many formalin-fixed paraffin-embedded specimens of different skin conditions. Her research has focused on squamous cell carcinoma and keratoacanthoma, a subtype of squamous cell carcinoma that can spontaneously resolve.

Our Smilow Cancer Hospital Care Center in Waterford welcomed Dr. Anca Bulgaru and Dr. Robert Legare with an open house at our beautiful facility highlighting cancer care services for women with breast cancer last evening. Welcome to Smilow and to Waterford, CT, Dr. Bulgaru and Dr. Legare!

"I love the idea that I can take science and the work at Yale Cancer Center and Smilow Cancer Hospital and bring those therapies to patients to help them live longer and better lives," Dr. Roy Herbst, Chief of Medical Oncology.

Recently, Dr. Daniel Petrylak accepted a donation from the Robert A. Welke Foundation to continue to support his research efforts. In December 2019, Enfortumab Vedotin (EV) was approved by the FDA for treatment of patients with resistant bladder cancer. The Welke Foundation was critical in providing support for research on EV. Their recent gift will continue to help fund research to further understand EV and help patients with bladder cancer.
Toma Tebaldi, PhD, has also been appointed to the Genomics, Genetics, and Epigenetics Research Program. Dr. Tebaldi is an Associate Research Scientist in the department of Internal Medicine (Hematology). His research goals are understanding the RNA molecular mechanisms underlying dysregulation in hematological malignancies by combining experimental and computational approaches and with focus on alternative splicing events, binding of non-coding RNAs and mutant RNA binding proteins, single cell expression data and RNA modifications (epitranscriptome).

Over 80 members of the Section of Medical Oncology are gathered at Water's Edge in Westbrook for a two-day retreat focused on the section's clinical, research, and education agenda for the coming year. Hosted by Section Chief Roy S. Herbst, MD, PhD, and co-chaired by Debra Brandt, DO, and Harriet Kluger, MD, the program includes faculty from our main campus, the VA, and all 15 Care Centers. A keynote presentation by Dr. Marc Brackett, author of Permission to Feel, was presented last night on, "Emotional Intelligence: From Theory to Practice to Systemic Change at Yale." Special thanks to Philip Grover for his spectacular organization of the event, and to Lisa DeChello, Allysia Matthews, PhD, Yang Zhou, PhD, MPH, Meina Wang, PhD, and Edward Kaftan, PhD, for their efforts in planning the program.
Employee Profile: Laura Donnelly

Laura Donnelly is treating the cancer-causing infection and other viruses.

Congratulations to @NitaAhujaMD elected as a member of the CT Academy of Science and Engineering. Dr. Ahuja is one of 15 honored from Yale as the leading experts in science, engineering, medicine & technology.

Today on @YaleCancerAnswers, @SmilowCancer socialworkers Laura Donnelly & Jessica Stein will discuss the important role of social work on our cancer care teams. Tune in to hear their perspective at 7:30pm on @wnpr or download our podcast @iTunes.

@DrAmerZeidan gives an overview of myeloid malignancies and immune checkpoint inhibition during a recent grand rounds.

Scientist-mentor @PolitiKaterina and @encheng23 join colleagues from Cancer Centers across the country in Washington today to participate in AACRontheHill to talk to lawmakers about the importance of funding cancer research.

Promising new research @NEJM by Dr. Lajos Pusztai for women with hard-to-treat triple-negative breast cancer. Findings show the immunotherapy drug Keytruda with chemotherapy reduces the risk of recurrence.

Thank you to Dr. Jorge Salmerón UNAM for giving our @YaleCancer Grand Rounds presentation today about Progress and Challenges concerning Cervical Cancer in Mexico.

Cancer Genetic Counselor Amanda Ganzak will join us on @YaleCancer Answers at 7:30pm to discuss the impact of genetics on cancer risk, and how to determine your risk. genetics Tune in to @wnpr or subscribe to our weekly podcast.
For Laura Donnelly, LCSW, it wasn't until she moved to Connecticut and volunteered at a cancer support agency that she realized that oncology social work was what she was "meant to do." For the last two and a half years as an outpatient clinical social worker at Smilow Cancer Hospital, she has supported the solid tumor medical oncology teams and their patients, meeting with them while they are on-site receiving treatment or meeting with their doctors.

Laura's principal role is to prioritize the emotional well-being of the patient. While she does help patients secure financial resources, transportation, and other needs, these requests often open a door to additional help and meaningful conversation. Supporting a patient's family members, loved ones, and caregivers who are greatly impacted by the patient's illness is also a critical aspect of oncology social work because at times, the goals and wishes of a patient are not the same as the caregiver.

Social work plays an important role in facilitating communication among family members and helping everyone get on the same page. This work that happens throughout the time of treatment can have a great impact on the final outcome of a person's end of life experience. "As people approach death," Laura says, "sometimes it is not always sad, but peaceful, because the patient has come to terms with how their story is going to end. They are able to look back over the chapters of their life and feel content."

---

@BarbaraBurtness gives commentary on a new study in @practiceupdate showing the detection of circulating tumor #HPVDNA in patients with #throatcancer after treatment can help identify recurrence & begin prompt treatment.

---

**Calendar**

**Hematology Research Seminar Series**
*March 6; 11:45 AM*
Brady Memorial Auditorium
*Beyond Immunophenotype: Classification of Pediatric Acute Leukemias with Myeloid Features by Genomic Profiling*
Tanja Gruber, MD, PhD
[Learn More >>]

**Neurology Clinical Grand Rounds**
*March 6, 12:00 PM*
Fitkin Memorial Pavilion Auditorium, LMP 1094
[Learn More >>]

**Yale Cancer Answers**
*March 8; 7:30 PM*
NPR
*Colorectal Cancer Awareness Month*
Xavier Llor, MD, PhD
[Learn More >>]

**Heart & Vascular Center Quality Grand Rounds**
*March 9; 5:00 PM*
55 Park Street, Park Street Auditorium
*Immune Checkpoint Inhibitor Cardiotoxicity: Establishing Standards for Diagnosis and Management*
Lauren Baldassarre, MD and Emily Ong
[Learn More >>]

**Genetics Clinical Grand Rounds**
*March 10; 10:15 AM*
Sterling Hall of Medicine, I-304
[Learn More >>]

**Yale Cancer Center Grand Rounds**
Laura loves her job and in addition to spending time with patients, she has enjoyed being part of a great team of social workers. Having others in the same line of work to talk with, share ideas, and gain support from has been a valuable resource. Additionally, she appreciates the access to professional development opportunities. She has been able to hear from a variety of speakers, attend ethics conferences on campus, join committees, and has had the opportunity to present at a melanoma symposium.

"(As a social worker), it is a privilege to enter into another person's life and learn their backgrounds, get to know them, and witness their strength and courage." says Laura. "All of these moments sustain you and their stories enrich your soul."

#OOTB Thanks!

YCC #OUTOFTHEBLUETHANKS recently recognized Christina Wiess, a Clinical Trials Team Manager in the Clinical Trials Office at Yale Cancer Center. When faced with unexpected challenges, Christina displayed truly heroic efforts in getting a patient enrolled in a study and treated in a timely fashion. The patient was incredibly grateful for her efforts and it is evident that Christina always has the patient's best interests in mind in everything that she does. Thank you, Christina!

March 10; 12:00 PM
55 Park Street, Park Street Auditorium
Yale Interventional Oncology Lab
David Madoff, MD | Julius Chapiro, MD, PhD | Jessica Santana, MS | Tal Zeevi, MS
Learn More >>

Laboratory Medicine Research Seminar
March 11; 12:00 PM
789 Howard Ave., Clinic Building, Rm. 401
Karla Kierkegaard
Learn More >>

Tai Chi Classes
March 11; 4:00 PM
CHH Center for Cancer Care, 200 Kennedy Drive, Torrington
Learn More >>

Therapeutic Radiology Grand Rounds
March 12; 9:00 AM
Smilow New Haven, North Pavilion, LL505
Beyond Oligometastasis: The Emerging Role of Stereotactic Radiation in Metastatic Disease
David Palma, MD, MSc, PhD, FRCPC
Learn More >>

Pharmacology Seminar
March 12; 12:30 PM
Brady Memorial Laboratory, B-131
Mapping Signaling Networks Governing Response and Resistance to EGFR Inhibitors in Lung Cancer
Sourav Bandyopadhyay, PhD
Learn More >>

Pathology Grand Rounds
March 12; 12:30 PM
Fitkin Memorial Pavilion Auditorium, LMP 1094
Novel Regulators of Bone Marrow Progenitor Cell Response to Cardiac Ischemic Injury
Gangjian Qin, MD, FAHA
Learn More >>

Cancer Genetics and Prevention Program Seminar
Yale Cancer Center's #OOTBTHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. All nominations should be submitted to the Director's Office c/o Anna Raso.

Recent Publications

Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura.
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI.
Read More >>

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Read More >>

Submissions
Please submit your recent publication and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications
Metabolic Syndrome, Exercise, and Cardiovascular Fitness in Breast Cancer Survivors
Knobf MT, Joen S.
Read More >>

Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.
Read More >>

Cell-penetrating peptide inhibits retromer-mediated human papillomavirus trafficking during virus entry.
Zhang P, Moreno R, Lambert PF, DiMaio D.
Read More >>

Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine.
de la Fuente MI, Rosenblum MK, Diamond EL, Tabar VS, Omuro A.
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 2;7(3).
Read More >>

Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration.
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.


Front Oncol. 2020 Feb 12;10:118.

National trends in palliative care use among older adults with cardiopulmonary and malignant conditions.

Feder SL, Jean RA, Bastian L, Akgün KM.

Heart Lung. 2020 Feb 27.

Surgically-Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database.

Sathe TS, Resio BJ, Hoag JR, Monsalve AF, Pathak R, Blasberg JD, Mase V Jr, Dhanasopon A, Boffa DJ.


**Pembrolizumab for Early Triple-Negative Breast Cancer.**
[Read More >>](#)

**Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.**
Kim DW, Lee G, Lee H, Mahal AR, Lam MB, Ng AK.
[Read More >>](#)

**Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.**
[Read More >>](#)

**Ku80-targeted pH-sensitive peptide-PNA conjugates are tumor selective and sensitize cancer cells to ionizing radiation.**
Mol Cancer Res. 2020 Feb 25.
[Read More >>](#)
Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer.


Transl Oncol. 2020 Feb 21;13(3):100742.

Funding Opportunities

Donaghue Foundation Greater Value Portfolio Grant
This program will fund research projects for two years with a maximum amount of $400,000 per award for the purpose of advancing promising approaches to achieve a higher value healthcare system. The goal of this program is to test approaches and tools that organizations can readily use to improve the value of the healthcare they provide to their patients and communities.

Application and Deadlines available: March 15, 2020

Damon Runyon Cancer Research Foundation Fellowship Award
The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention.

Application Deadline: March 16, 2020

Sontag Foundation Distinguished Scientist Award
This award provides career and research support to early career scientists who
demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.

**Application Deadline:** March 16, 2020

**Learn More >>**

**Yale Cancer Center-Advanced Training Program for Physician-scientists Award**

YCC-ATPP is a two-year T32 training program that provides salary and research funds for two third-year Hematology/Oncology (Hem/Onc) fellows each year who are strongly committed to be independent physician-scientists performing basic, translational, clinical, or outcomes research in a cancer-related field.

**Application Deadline:** March 16, 2020

**Learn More >>**

**Vera and Joseph Dresner Foundation MDS Research Fund: Early Career Awards and Established Investigator**

This fund will expand the foundation's investments in support of cutting-edge MDS research and related programs that will lead to the future standards of care and ultimately cure.

**Letters of Intent Due:** March 20, 2020

**Learn More >>**

**Prostate Cancer Foundation Young Investigator Awards**

The Prostate Cancer Foundation champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer.

**Application Deadline:** March 23, 2020

**Learn More >>**

**Charles H. Hood Foundation Child Health Research Awards Program**

The intent of this Awards Program is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist
in the transition to other sources of research funding.
March 27, 2020
Learn More >>

The Harrington Scholar-Innovator Award
This Award recognizes physician-scientist innovators throughout the US and Canada, whose research has the potential to change standard of care. The Scholar-Innovator Award provides research and drug development support to help bridge the gap between basic discovery and the clinical realm.

Letter of Intent Due: March 27, 2020
Learn More >>

Human Frontier Science Program Research Grants (Program Grants & Young Investigators)
HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries

Letters of Intent Due: March 30, 2020
Learn More >>

The Pew-Stewart Scholars for Cancer Research
The Pew Scholars Program for Cancer Research provides funding to young investigators of outstanding promise in science relevant to the advancement of a cure for cancer.

Letter of Intent Due: March 31, 2020
Learn More >>

Alex’s Lemonade Stand Familial RUNX1 Grant Program
The RUNX1 Research Program is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloid leukemia (AML) due to germline RUNX1
mutations with the ultimate goal of developing effective therapies to prevent the onset of AML.

April 1, 2020

Learn More >>

Cancer Research Institute Postdoctoral Fellowship
The CRI Irvington Postdoctoral Fellowship Program supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology.

Application Deadline: April 1, 2020

Learn More >>

Breast Cancer Alliance Exceptional Project Grant
Breast Cancer Alliance invites clinical doctors and research scientists at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique, and innovative research.

Letter of Intent Due: April 5, 2020

Learn More >>

Prostate Cancer Foundation 2020 PCF Challenge Awards
The PCF is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received.

April 17, 2020

Learn More >>

Yale SPORE in Lung Cancer Career Enhancement Program (CEP)
The CEP of the Yale SPORE in Lung Cancer has been established to educate the next generation of investigators committed to translational research in lung cancer. The CEP
will provide support of up to $50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research.

**Letters of Intent Due:** April 24, 2020

[Learn More >>]

**Yale SPORE in Lung Cancer Developmental Research Program (DRP) Award**

The DRP of the Yale SPORE in Lung Cancer provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full Yale SPORE in Lung Cancer project. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications.

**Letters of Due:** April 24, 2020

[Learn More >>]

**The Mark Foundation Emerging Leader Award**

This Award provides grant support to early career investigators conducting high-impact, high-risk cancer research. This award is intended to support highly promising projects for which other sources of funding are not readily available or for a separate innovative endeavor that will allow the applicant to pursue a distinct and novel research direction.

**Letter of Intent Due:** May 10, 2020

[Learn More >>]

**Ovarian Cancer Research Fund Alliance Collaborative Research Development Grant**

This Grant provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions.

**Letter of Intent Due:** May 15, 2020

[Learn More >>]
Alex's Lemonade Stand Foundation
Psychosocial Family Impact Grants
These Grants focus on psychosocial and behavioral health outcomes for children diagnosed with cancer and their families.
Letter of Intent Due: June 15, 2020
Learn More >>

Alex's Lemonade Stand Foundation
Psychosocial Launch Grants
These Grants focus on psychosocial and behavioral health outcomes for children diagnosed with cancer and their families.
Letter of Intent Due: June 15, 2020
Learn More >>

Breast Cancer Alliance Young Investigator Grant
To encourage a commitment to breast cancer research, Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers, to apply for funding for the Young Investigator Grant.
Application Deadline: July 24, 2020
Learn More >>